Table 1 Study subjects MRD marker .... | American Society of Hematology

Table 1

Study subjects

MRD marker	NPM1c⁺	PML-RARA	CBFB-MYH11	RUNX1-RUNX1T1
No. of patients	180	406*	47	56
Patients with HR	54	22*	19	20
Patients in CCR	126	363*	28	36
CCR samples	193	1865	151	170
Relapse kinetics
Patients included	22	8	9	7
Patients excluded	32	13	10	13
Reasons for exclusion:
No MR/HR sample	32	9	10	12
Administration of pre- emptive therapy in MR	0	4	0	1
CNS relapse	0	1	0	0
Relapse modeling
Patients included	31	13	14	11
Samples	70	61	59	46
Patients excluded	23	8	5	9
Reasons for exclusion:
No mCR	3	1	0	1
No CR samples^†	20	4	5	7
Administration of pre- emptive therapy in MR	0	3	0	1
CNS relapse	0	1	0	0

MRD marker	NPM1c⁺	PML-RARA	CBFB-MYH11	RUNX1-RUNX1T1
No. of patients	180	406*	47	56
Patients with HR	54	22*	19	20
Patients in CCR	126	363*	28	36
CCR samples	193	1865	151	170
Relapse kinetics
Patients included	22	8	9	7
Patients excluded	32	13	10	13
Reasons for exclusion:
No MR/HR sample	32	9	10	12
Administration of pre- emptive therapy in MR	0	4	0	1
CNS relapse	0	1	0	0
Relapse modeling
Patients included	31	13	14	11
Samples	70	61	59	46
Patients excluded	23	8	5	9
Reasons for exclusion:
No mCR	3	1	0	1
No CR samples^†	20	4	5	7
Administration of pre- emptive therapy in MR	0	3	0	1
CNS relapse	0	1	0	0

MRD indicates minimal residual disease; HR, hematologic relapse; CR, complete remission; CCR, continuous CR; MR, molecular relapse; mCR, molecular CR; and CNS, central nervous system.

Numbers do not add, as some patients were successfully treated in first MR.

†

In the 12 months prior to HR, there were no CR samples.

View Large

This Feature Is Available To Subscribers Only